Effect of Osimertinib Mesylate Combined with Platinum Containing Dual Drug Chemotherapy in Patients with EGFR Mutated Advanced Non-small Cell Lung Cancer on Related Indexes of EGF and IGF
Objective:To investigate the effect of Osimertinib Mesylate in patients with advanced non-small cell lung cancer and influence on related indexes of epidermal growth factor(EGF)and insulin like growth factor(IGF).Method:A total of 100 patients with epidermal growth factor receptor(EGFR)mutated advanced non-small cell lung cancer in the First Affiliated Hospital of Xiamen University from January 2021 to November 2022 were divided into control group(n=50)and observation group(n=50)by the random number table method.The control group was treated with platinum containing dual drug chemotherapy,the observation group was treated with Osimertinib Mesylate on the treatment of control group.Then the treatment effect of non-small cell lung cancer,incidence of adverse reaction,EGF and EGFR,IGF related indexes[insulin like growth factorⅠ(IGF-Ⅰ),insulin like growth factor Ⅱ(IGF-Ⅱ),insulin like growth factor Ⅰ receptor(IGF-ⅠR)and insulin like growth factor binding protein-3(IGFBP-3)]of two groups were compared.Result:The total effective rate of non-small cell lung cancer treatment of observation group was significantly higher than that of control group,the difference was statistically significant(P<0.05).There were no statistically significant differences in the incidences of adverse reactions between the two groups(P>0.05).Before the treatment,the EGF and EGFR,IGF related indexes of two groups were compared,the differences were not statistically significant(P>0.05);after 2 and 4 cycles of treatment,the levels of EGF and EGFR,IGF-Ⅰ,IGF-Ⅱ and IGF-ⅠR of observation group were significantly lower than those of control group,the levels of IGFBP-3 were significantly higher than those of control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Osimertinib Mesylate in patients with EGFR mutated advanced non-small cell lung cancer is better,and it can significantly improve the expression of related indexes of EGF and IGF,so its application value in the patients with advanced non-small cell lung cancer is higher.
万方数据
维普
